Recent advances in the diagnosis and management of cardiac amyloidosis

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


The heart is commonly involved in various forms of amyloidosis and cardiomyopathy is a major cause of morbidity and mortality in these patients. Diagnosis of cardiac amyloidosis is often delayed due to nonspecific presenting symptoms and failure to recognize early signs of amyloid heart disease on routine cardiac imaging. Treatment of cardiac amyloidosis depends upon the type of amyloid protein. Systemic chemotherapy with or without stem cell transplantation is used to treat immunoglobulin-related amyloidosis and liver transplantation is used for familial transthyretin amyloidosis in select patients. Clinical trials with siRNA for the treatment of transthyretin amyloid cardiomyopathies and amyloid protein stabilizers are ongoing. Prognosis depends on the type of amyloid protein with poorer outcomes noted in immunoglobulin light-chain amyloidosis. Supportive care forms the cornerstone of management and advancements in cardiac imaging and proteomics are expected to positively impact our ability to diagnose, prognosticate and treat cardiac amyloidosis.

Original languageEnglish (US)
Pages (from-to)131-146
Number of pages16
JournalFuture Cardiology
Issue number1
StatePublished - Jan 2014


  • amyloid cardiomyopathy
  • amyloid heart disease
  • cardiac amyloidosis

ASJC Scopus subject areas

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Recent advances in the diagnosis and management of cardiac amyloidosis'. Together they form a unique fingerprint.

Cite this